A Comprehensive Monograph on the Fixed-Dose Combination of Sitagliptin and Metformin

Executive Summary and Introduction

Overview of Sitagliptin/Metformin Combination Therapy

The fixed-dose combination (FDC) of sitagliptin and metformin hydrochloride represents a significant therapeutic modality in the management of type 2 diabetes mellitus (T2DM). This oral antihyperglycemic agent is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients for whom treatment with both sitagliptin and metformin is appropriate.[1] The development and clinical application of this combination therapy reflect a strategic evolution in diabetes management, moving from a traditional, sequential addition of medications to a more proactive approach of using initial or early combination therapy to target the multiple pathophysiological defects inherent in T2DM.[3]

Type 2 diabetes is a chronic and progressive metabolic disorder characterized by insulin resistance, relative insulin deficiency due to pancreatic β-cell dysfunction, and excessive hepatic glucose production.[5] As the disease progresses, monotherapy, typically with metformin, often becomes insufficient to maintain target glycemic control, with over 50% of patients requiring additional therapeutic agents.[5] International and national clinical guidelines now recognize the utility of initiating combination therapy earlier in the treatment course, particularly for patients with higher baseline glycosylated hemoglobin (HbA1c) levels (e.g.,

), to achieve glycemic goals more rapidly and durably.[7] The combination of sitagliptin and metformin provides a powerful tool to implement this strategy, offering complementary mechanisms of action that address both insulin resistance and impaired insulin secretion.[8] Furthermore, the availability of an FDC tablet simplifies the treatment regimen, which can lead to improved patient adherence compared to taking multiple individual pills, a critical factor in managing a chronic condition like T2DM.[8]

Drug Identification and Formulations

The combination medication consists of two distinct active pharmaceutical ingredients:

• Sitagliptin: A member of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.[11]
• Metformin: A member of the biguanide class of drugs.[1]

This FDC is marketed under several brand names globally, including Janumet, Janumet XR, Zituvimet, and Zituvimet XR.[1] It is available in two primary formulations that differ in their drug-release profiles and dosing frequency:

1. Immediate-Release (IR): Marketed as Janumet and Zituvimet, this formulation releases both active ingredients promptly after ingestion and is administered twice daily.[1]
2. Extended-Release (XR): Marketed as Janumet XR and Zituvimet XR, this formulation contains sitagliptin for immediate release and metformin in an extended-release matrix, allowing for convenient once-daily administration.[4]

Place in Therapy and Limitations of Use

The sitagliptin/metformin FDC is established as a key option within the T2DM treatment algorithm. It is frequently prescribed as a second-line therapy for patients who are inadequately controlled on metformin monotherapy.[5] It is also indicated for initial therapy in certain drug-naïve patients, particularly those with significantly elevated baseline HbA1c levels where monotherapy is unlikely to achieve target control.[7]

Despite its broad utility, there are critical limitations to its use. The medication is not indicated for the treatment of type 1 diabetes mellitus or for the management of diabetic ketoacidosis (DKA), as its mechanisms of action are ineffective in these insulin-deficient states.[3] Additionally, the combination has not been studied in patients with a history of pancreatitis, and it remains unknown whether such patients are at an increased risk for developing pancreatitis while taking this medication.[3]

Detailed Pharmacology and Mechanism of Action

The Sitagliptin Component: DPP-4 Inhibition and the Incretin System

The pharmacological action of sitagliptin is centered on the potentiation of the endogenous incretin system, a key physiological pathway in glucose homeostasis. The "incretin effect" describes the clinical observation that an oral glucose load stimulates a substantially greater insulin response—three to four times higher—than an intravenous glucose infusion that produces an identical level of glycemia.[5] This phenomenon is mediated by gut-derived hormones known as incretins, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).[22] Secreted by L-cells and K-cells of the intestine in response to nutrient ingestion, these hormones play several crucial roles in metabolic regulation [21]:

• They stimulate the synthesis and secretion of insulin from pancreatic β-cells in a glucose-dependent manner, meaning their insulinotropic effect is pronounced when blood glucose is elevated and diminishes as glucose levels normalize.[5]
• GLP-1 also suppresses the secretion of glucagon from pancreatic α-cells, which in turn reduces hepatic glucose production.[22]
• Additional effects of GLP-1 include delaying gastric emptying and promoting satiety, which can contribute to better postprandial glucose control and weight management.[24]

The physiological activity of GLP-1 and GIP is short-lived, with a plasma half-life of only a few minutes. This is due to their rapid inactivation by the ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves the active peptides into inactive metabolites.[5] In patients with T2DM, the incretin effect is often blunted, contributing to postprandial hyperglycemia.[21]

Sitagliptin is a potent, highly selective, and orally active inhibitor of the DPP-4 enzyme.[5] By binding to and inhibiting DPP-4, sitagliptin prevents the degradation of active GLP-1 and GIP. This action prolongs their half-life and results in a two- to three-fold increase in their circulating concentrations.[5] The elevated levels of active incretins enhance the glucose-dependent stimulation of insulin secretion and suppression of glucagon release, thereby improving glycemic control throughout the day, particularly after meals.[22] The glucose-dependent nature of this mechanism is a fundamental pharmacological feature that confers a very low intrinsic risk of hypoglycemia when sitagliptin is used as monotherapy or in combination with metformin. Unlike agents such as sulfonylureas, which stimulate insulin release regardless of ambient glucose levels, sitagliptin works by amplifying a natural, self-regulating feedback loop.[21] This distinction is a primary reason for its favorable safety profile and its suitability as a combination partner for metformin.

The Metformin Component: A Multi-Target Biguanide

Metformin, a biguanide, has been a first-line therapy for T2DM for decades, yet its molecular mechanisms of action are complex and continue to be elucidated.[5] It exerts its antihyperglycemic effects through multiple pathways without stimulating insulin secretion, which explains its low risk of causing hypoglycemia when used alone.[27] The principal and most well-established mechanism is the reduction of hepatic glucose production (gluconeogenesis).[2] Metformin is thought to achieve this primarily through the inhibition of mitochondrial respiratory chain complex I, which leads to an increase in the cellular AMP:ATP ratio and subsequent activation of AMP-activated protein kinase (AMPK).[27] Activated AMPK then phosphorylates and inhibits key enzymes involved in gluconeogenesis.

In addition to its primary hepatic action, metformin contributes to glycemic control through several other important mechanisms:

• Improved Peripheral Insulin Sensitivity: Metformin enhances glucose uptake and utilization in peripheral tissues, particularly skeletal muscle, by improving insulin signaling and promoting the translocation of GLUT4 glucose transporters to the cell membrane.[2] This action helps to combat the underlying insulin resistance characteristic of T2DM.
• Reduced Intestinal Glucose Absorption: Metformin has been shown to decrease the absorption of glucose from the gastrointestinal tract, further contributing to lower postprandial glucose levels.[2]
• Actions within the Gastrointestinal Tract: A significant portion of an oral metformin dose is not absorbed and accumulates at high concentrations within the gut mucosa.[29] Emerging research indicates that metformin exerts direct effects within the gut, including altering the composition of the gut microbiome and, importantly, stimulating the secretion of GLP-1 from intestinal L-cells.[28]

This latter mechanism, the stimulation of GLP-1 secretion, provides a new dimension to the synergy between metformin and sitagliptin. The interaction is not merely a combination of a drug acting on the liver and muscle with another acting on the pancreas; it involves both drugs converging on the same hormonal system within the gut.

Pharmacological Synergy and Additive Effects

The combination of sitagliptin and metformin is pharmacologically rational because their distinct mechanisms of action are complementary, targeting multiple core defects of T2DM.[5] Sitagliptin addresses impaired insulin secretion and dysregulated glucagon release by enhancing the incretin system, while metformin primarily targets insulin resistance and excessive hepatic glucose production.[5]

The synergy extends beyond this complementary organ-level action. As noted, both drugs directly influence the GLP-1 pathway. Metformin appears to increase the secretion of GLP-1 from the gut, while sitagliptin inhibits the DPP-4 enzyme that would otherwise rapidly degrade it.[5] This dual action creates a more potent and sustained elevation of active GLP-1 levels than either agent can achieve alone, leading to an additive or even synergistic effect on glycemic control.[5]

Clinical studies have quantified this additive efficacy. In a 24-week trial involving drug-naïve patients, sitagliptin monotherapy (100 mg/day) lowered placebo-adjusted HbA1c by approximately 0.8%, and metformin monotherapy (1000 mg/day) lowered it by 1.0%. The initial combination of sitagliptin 100 mg/day and metformin 1000 mg/day, however, produced a placebo-adjusted HbA1c reduction of 1.6%.[4] In another study, the combination of sitagliptin 50 mg/metformin 1000 mg lowered HbA1c by approximately 1.9% from baseline, a reduction substantially greater than the ~0.7% seen with sitagliptin alone or the ~1.1% with metformin alone, demonstrating a clear additive clinical response.[15] This robust, additive glycemic improvement confirms that the combination effectively addresses the multifaceted pathophysiology of T2DM.[35]

Clinical Efficacy in Type 2 Diabetes Mellitus

Review of Pivotal Clinical Trials

The clinical efficacy of the sitagliptin and metformin combination has been robustly established in a comprehensive program of Phase III clinical trials. These studies have evaluated the combination across the spectrum of T2DM management, from initial therapy in drug-naïve patients to add-on therapy in those with inadequate glycemic control on existing treatments.

As initial therapy, a 24-week, randomized, double-blind, placebo-controlled factorial study in 1,091 drug-naïve patients demonstrated the superior efficacy of co-administering sitagliptin and metformin compared to either agent alone.[4] Patients with a mean baseline HbA1c of 8.8% who received initial therapy with sitagliptin 100 mg/day and metformin 2000 mg/day experienced a mean placebo-adjusted HbA1c reduction of 2.1%.[4] This was significantly greater than the reductions seen with metformin 2000 mg/day alone (1.3%) or sitagliptin 100 mg/day alone (0.8%).[4]

As add-on therapy, multiple studies have confirmed the benefit of adding sitagliptin to ongoing metformin treatment. In a landmark 24-week trial, patients with a mean baseline HbA1c of 8.0% who were inadequately controlled on metformin (≥1500 mg/day) had sitagliptin 100 mg/day or placebo added to their regimen. The sitagliptin group achieved a mean placebo-subtracted HbA1c reduction of 0.65% to 0.7%.[18] Similar efficacy has been demonstrated when sitagliptin is added as part of a triple-therapy regimen with metformin and a sulfonylurea.[37]

In comparative efficacy trials, the sitagliptin/metformin combination has demonstrated favorable outcomes. A 32-week study comparing initial therapy with Janumet (up-titrated to 50 mg/1000 mg twice daily) against pioglitazone monotherapy (45 mg once daily) in patients with a mean baseline HbA1c of 8.9% found that the combination therapy resulted in a significantly greater mean HbA1c reduction (1.9% vs. 1.4%).[39]

Impact on Glycemic Parameters

Across the clinical trial program, the sitagliptin/metformin combination has consistently demonstrated substantial improvements in key glycemic parameters.

• Glycosylated Hemoglobin (HbA1c): The magnitude of HbA1c reduction is a primary measure of efficacy. As initial combination therapy, reductions of up to 2.1% from a baseline of 8.8% have been observed.[4] As add-on therapy to metformin, the additional reduction is typically in the range of 0.65% to 0.9%.[18] The degree of HbA1c reduction is strongly correlated with the baseline HbA1c level; patients with higher initial HbA1c values (e.g., >9%) experience the largest reductions.[40] A significant proportion of patients achieve the American Diabetes Association (ADA) recommended therapeutic target of HbA1c <7.0%. In one initial therapy trial, 66% of patients on the high-dose combination reached this goal, compared to only 38% on high-dose metformin monotherapy.[4]
• Fasting and Postprandial Glucose: The combination therapy also leads to significant reductions in both fasting plasma glucose (FPG) and 2-hour postprandial glucose (PPG).[36] In an initial therapy study, the combination of sitagliptin 100 mg/metformin 2000 mg reduced FPG by a placebo-adjusted mean of 52.3 mg/dL.[36] The improvement in PPG is particularly notable, reflecting sitagliptin's mechanism of enhancing meal-stimulated insulin secretion.[41]

The table below summarizes the glycemic efficacy results from key clinical trials.

Study/Reference	Patient Population	Baseline HbA1c (Mean)	Treatment Arms	Duration (Weeks)	Placebo-Adjusted Mean HbA1c Reduction	Patients Achieving HbA1c <7.0%
Goldstein et al. (2007) 4	Drug-naïve	8.8%	Sitagliptin 100 mg + Metformin 2000 mg	24	-2.1%	66%
		8.8%	Metformin 2000 mg	24	-1.3%	38%
		8.8%	Sitagliptin 100 mg	24	-1.0%	20%
Charbonnel et al. (2006) 38	Metformin add-on	8.0%	Sitagliptin 100 mg + Metformin ≥1500 mg	24	-0.65%	~47%
		8.0%	Placebo + Metformin ≥1500 mg	24	+0.02%	~18%
Engel et al. (2015) 39	Drug-naïve	8.9%	Sitagliptin/Metformin (up-titrated)	32	-1.9% (from baseline)	57%
		8.9%	Pioglitazone 45 mg	32	-1.4% (from baseline)	43%

Long-Term Glycemic Durability and Non-Glycemic Benefits

Beyond initial efficacy, the durability of glycemic control is a critical consideration in a progressive disease like T2DM. The Combination of Sitagliptin and Metformin in Clinical Practice (COSMIC) study, a real-world observational study, demonstrated a persistent glucose-lowering effect of initial combination therapy for up to four years. After one year, 72.2% of patients were classified as responders (defined as HbA1c reduction ≥0.8% or attainment of HbA1c ≤7.0%), and after four years, 35.4% of patients still maintained this response on the initial therapy.[44]

In addition to glycemic control, the sitagliptin/metformin combination offers important non-glycemic benefits:

• Body Weight: Unlike many other antihyperglycemic agents (e.g., sulfonylureas, thiazolidinediones, insulin) that are associated with weight gain, the sitagliptin/metformin combination is generally weight-neutral or may lead to modest weight loss.[9] In a comparative trial, patients on the combination therapy experienced a mean weight loss of 1.4 kg, whereas patients on pioglitazone gained 3.0 kg.[39] This is a significant clinical advantage, as many patients with T2DM are overweight or obese.
• β-cell Function: Clinical trials have consistently shown that the combination therapy improves surrogate markers of pancreatic β-cell function, including the homeostasis model assessment of β-cell function (HOMA-β) and the proinsulin-to-insulin ratio.[7] This suggests that the therapy may help to preserve the function of insulin-producing cells, although the long-term impact on disease progression requires further study.

Dosage, Formulations, and Administration

Available Formulations and Strengths

The sitagliptin and metformin hydrochloride FDC is available in both immediate-release (IR) and extended-release (XR) tablets, offering flexibility in dosing regimens. The available strengths are expressed as mg of sitagliptin / mg of metformin HCl.[1]

Immediate-Release (IR) Tablets (e.g., Janumet, Zituvimet):

• 50 mg / 500 mg
• 50 mg / 850 mg
• 50 mg / 1000 mg

Extended-Release (XR) Tablets (e.g., Janumet XR, Zituvimet XR):

• 50 mg / 500 mg
• 50 mg / 1000 mg
• 100 mg / 1000 mg

Dosing and Titration Guidelines

The dosage of the sitagliptin/metformin FDC must be individualized based on the patient's current therapeutic regimen, effectiveness, and tolerability, while adhering to the maximum recommended daily doses of 100 mg for sitagliptin and 2000 mg for metformin.[1]

For Patients Not Currently Treated with Metformin:

• Immediate-Release (IR): The recommended starting dose is 50 mg sitagliptin/500 mg metformin taken orally twice daily.[2]
• Extended-Release (XR): The recommended starting dose is 100 mg sitagliptin/1000 mg metformin taken orally once daily.[2]
• For both formulations, gradual dose escalation of the metformin component is recommended to reduce the gastrointestinal side effects commonly associated with metformin initiation.[20]

For Patients Already Treated with Metformin:

• The starting dose should provide a total daily dose of 100 mg of sitagliptin (50 mg twice daily for IR, 100 mg once daily for XR) and continue the patient's current daily dose of metformin.[1]
• Conversion Example (IR): For a patient taking metformin HCl 850 mg twice daily, the recommended starting dose of the IR FDC is 50 mg sitagliptin/1000 mg metformin twice daily.[1]
• Conversion Example (XR): For a patient taking metformin HCl immediate-release 850 mg or 1000 mg twice daily, the recommended starting dose of the XR FDC is two 50 mg sitagliptin/1000 mg metformin XR tablets taken together once daily to achieve a total dose of 100 mg sitagliptin/2000 mg metformin XR.[2]

The availability of an extended-release, once-daily formulation is a clinically important advancement. T2DM is a chronic condition requiring lifelong adherence to medication, which can be challenging with complex, multi-dose regimens.[5] By reducing the pill burden and dosing frequency, the XR formulation is designed to improve long-term patient adherence, a key determinant of successful glycemic management.[4] The specific guidelines for converting patients from twice-daily IR metformin to once-daily XR FDC are structured to ensure a seamless transition without compromising efficacy or introducing dosing errors, thereby facilitating the adoption of this more convenient regimen.[1]

Administration and Patient Counseling

Proper administration is crucial for the efficacy and tolerability of the medication. Patients should be counseled on the following points:

• Immediate-Release (Janumet): Take orally twice daily with meals to minimize gastrointestinal side effects.[11]
• Extended-Release (Janumet XR): Take orally once daily with the evening meal. Taking it with food, particularly the evening meal, helps reduce potential stomach upset that can occur in the first few weeks of treatment.[2] If the dose requires two XR tablets, both should be taken together at the same time.[48]
• Swallowing Tablets: All tablets, both IR and XR, must be swallowed whole. They should not be split, cut, crushed, or chewed before swallowing.[11] This is especially critical for the XR formulation to maintain its extended-release properties.
• "Ghost Tablet" Phenomenon: Patients taking the XR formulation may notice something in their stool that resembles the tablet. They should be reassured that this is the non-dissolvable shell of the tablet passing through the digestive system after the medication has been absorbed. It is a normal occurrence and does not indicate a lack of efficacy.[2]

Comprehensive Safety Profile and Risk Management

The safety profile of the sitagliptin/metformin combination is well-characterized and is largely reflective of the known profiles of its individual components. The overall risk management strategy is dominated by the need to mitigate the risks associated with metformin, particularly lactic acidosis, while also requiring vigilance for the distinct, class-specific adverse events related to sitagliptin.

Common and Mild Adverse Effects

The most frequently reported adverse effects are typically mild to moderate in intensity and often transient, particularly the gastrointestinal symptoms, which tend to diminish over time or with dose adjustment.[55] Common side effects include [3]:

• Gastrointestinal Disturbances: Diarrhea, nausea, vomiting, flatulence, indigestion, and abdominal pain are very common, primarily due to the metformin component.[55] Taking the medication with food and starting with a low dose that is gradually titrated upwards can significantly reduce the incidence and severity of these effects.[11]
• Upper Respiratory Tract Infection: Symptoms such as stuffy or runny nose and sore throat are commonly reported.[3]
• Headache: This is another common side effect reported in clinical trials.[11]
• Other: Weakness and a metallic taste in the mouth (from metformin) may also occur.[56]

Serious Adverse Reactions and Warnings

While generally well-tolerated, the sitagliptin/metformin combination is associated with several rare but serious adverse reactions that require immediate medical attention.

Boxed Warning: Metformin-Associated Lactic Acidosis (MALA)

The U.S. Food and Drug Administration (FDA) has issued a boxed warning for all metformin-containing products, including the sitagliptin/metformin FDC, regarding the risk of metformin-associated lactic acidosis (MALA).[49]

• Description and Severity: MALA is a rare metabolic complication that can occur due to metformin accumulation in the blood. When it occurs, it is a medical emergency with a reported mortality rate of up to 50%.[3]
• Pathophysiology: The primary cause of MALA is the accumulation of metformin to toxic levels, most often due to impaired renal clearance. High concentrations of metformin inhibit complex I of the mitochondrial respiratory chain, which impairs oxidative phosphorylation and forces a shift to anaerobic metabolism. This leads to the overproduction of lactate and, coupled with impaired hepatic lactate clearance, results in severe metabolic acidosis.[63]
• Risk Factors: The single most important risk factor for MALA is renal impairment. Other significant risk factors that can lead to metformin accumulation or tissue hypoxia include:
• Renal impairment (eGFR < 30 mL/min/1.73 m² is a contraindication) [66]
• Age 65 years or older [61]
• Acute or chronic excessive alcohol intake [19]
• Severe hepatic impairment [64]
• Conditions associated with hypoxia, such as acute congestive heart failure, shock, sepsis, or recent myocardial infarction [63]
• Dehydration from any cause (e.g., severe vomiting, diarrhea, fever) [67]
• Major surgical procedures or intravascular administration of iodinated contrast agents [63]
• Clinical Presentation: The onset of MALA is often subtle and can be missed. Initial symptoms are nonspecific and may include malaise, myalgia (muscle pain), respiratory distress, increasing somnolence, and abdominal pain.[61] As the condition worsens, more severe signs such as hypothermia, hypotension, and resistant bradyarrhythmias can develop.[61] Any patient on metformin presenting with metabolic acidosis without evidence of ketoacidosis should be evaluated for MALA.[64]
• Management: MALA is a medical emergency. If suspected, the sitagliptin/metformin medication must be discontinued immediately, and the patient must be hospitalized. General supportive measures should be instituted, and prompt hemodialysis is recommended to correct the acidosis and efficiently remove the accumulated metformin from the blood.[61]

Pancreatitis

Postmarketing reports have identified acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, in patients taking sitagliptin.[3] Patients should be counseled to seek immediate medical care if they experience severe, persistent abdominal pain, which may or may not be accompanied by vomiting and may radiate to the back. If pancreatitis is suspected, the medication should be promptly discontinued.[17]

Heart Failure

While not observed directly in sitagliptin trials, an increased rate of hospitalization for heart failure has been observed with other DPP-4 inhibitors.[22] Therefore, prescribers should consider the risks and benefits of initiating this FDC in patients with known risk factors for heart failure, such as a history of heart failure or renal impairment.[66] Patients should be monitored for signs and symptoms of heart failure, including increasing shortness of breath (especially when lying down), rapid and unusual weight gain, and peripheral edema (swelling in the feet, ankles, or legs).[3]

Hypoglycemia

When used alone, the sitagliptin/metformin combination has a low risk of causing hypoglycemia due to the glucose-dependent mechanism of sitagliptin and the non-secretagogue action of metformin.[18] However, the risk of hypoglycemia is significantly increased when the FDC is co-administered with an insulin secretagogue (e.g., a sulfonylurea) or with insulin.[1] In such cases, a dose reduction of the concomitant insulin or sulfonylurea may be necessary to minimize this risk.[14]

Renal Function

Postmarketing cases of worsening renal function and acute renal failure, sometimes requiring dialysis, have been reported.[62] This underscores the critical importance of assessing renal function prior to initiation and monitoring it at least annually thereafter.

Hypersensitivity and Severe Skin Reactions

Serious hypersensitivity reactions have been reported with sitagliptin. These can include anaphylaxis, angioedema (swelling of the face, lips, tongue, and throat that can cause difficulty breathing or swallowing), and severe exfoliative skin conditions such as Stevens-Johnson syndrome.[3] Additionally, bullous pemphigoid, a skin condition that can cause large blisters and erosions requiring hospitalization, has been reported in patients taking DPP-4 inhibitors.[3] Patients should be advised to report any development of rash, blisters, or skin erosions immediately.

Other Clinically Significant Effects

• Severe and Disabling Arthralgia: The FDA has warned that DPP-4 inhibitors can cause severe and disabling joint pain (arthralgia).[22] The onset can be from one day to years after starting the drug. If a patient develops severe joint pain, discontinuation of the medication should be considered.[58]
• Vitamin B12 Deficiency: Long-term use of metformin is associated with a decrease in serum vitamin B12 levels due to interference with its absorption.[58] This can rarely lead to megaloblastic anemia. It is recommended to monitor hematologic parameters annually and vitamin B12 levels periodically (e.g., every 2-3 years), especially in patients with pre-existing risk factors.[49]

Contraindications and Use in Specific Populations

Absolute Contraindications

The use of sitagliptin/metformin is absolutely contraindicated in the following patient populations and conditions:

• Severe Renal Impairment: Patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m².[1]
• Metabolic Acidosis: Patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis (with or without coma).[1]
• Hypersensitivity: Patients with a history of a serious hypersensitivity reaction (e.g., anaphylaxis, angioedema) to sitagliptin, metformin, or any of the excipients in the formulation.[1]

Precautions and Special Considerations

In addition to absolute contraindications, there are several situations where the medication should be used with caution or temporarily discontinued to mitigate risk.

• Iodinated Contrast Procedures: Metformin should be temporarily discontinued at the time of or prior to an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m², in patients with a history of hepatic impairment, alcoholism, or heart failure, or in any patient who will be administered intra-arterial iodinated contrast. Renal function should be re-evaluated 48 hours after the procedure, and the medication should be restarted only if renal function is stable.[20]
• Surgical Procedures: It is recommended to temporarily withhold the medication for any surgical procedure that requires restricted food or fluid intake. Therapy can be restarted once the patient's oral intake has resumed and renal function has been verified as stable.[2]
• Hypoxic States and Dehydration: The medication should be promptly withheld in the presence of any condition associated with hypoxemia (e.g., acute heart failure, sepsis) or dehydration, due to the increased risk of lactic acidosis.[2]

Guidance for Specific Patient Groups

• Renal Impairment: The dosing and use of sitagliptin/metformin are critically dependent on renal function, as measured by eGFR. The shift from using serum creatinine to the more accurate eGFR represents a significant evolution in the drug's safety labeling, allowing for more precise risk stratification.[76]
• eGFR ≥ 45 mL/min/1.73 m²: No dose adjustment is typically required. Renal function should be monitored regularly.[50]
• eGFR 30 to < 45 mL/min/1.73 m²: Initiation of the FDC is not recommended. For patients already on therapy whose eGFR falls into this range, the benefits and risks of continuing treatment should be carefully assessed. The fixed-dose combination may be inappropriate because these patients require a reduced dose of sitagliptin (e.g., 50 mg/day) that may not be available in all FDC strengths.[20]
• eGFR < 30 mL/min/1.73 m²: The medication is contraindicated.[1]
• Hepatic Impairment: Because impaired hepatic function has been associated with some cases of lactic acidosis, the use of sitagliptin/metformin should generally be avoided in patients with clinical or laboratory evidence of hepatic disease.[2]
• Geriatric Population (≥65 years): Elderly patients are more likely to have a decreased renal function and are at a higher risk for MALA. Therefore, dose selection should be cautious, and renal function should be monitored more frequently in this population.[48] Metformin should not be initiated in patients ≥80 years of age unless their renal function is confirmed to be normal.[64]
• Pregnancy and Lactation: There are no adequate and well-controlled studies of sitagliptin/metformin in pregnant women; therefore, its use should be considered only if the potential benefit justifies the potential risk to the fetus.[15] Metformin is known to pass into breast milk in small amounts, so caution should be exercised when administering the drug to a nursing woman.[15]
• Females of Reproductive Potential: Metformin may induce ovulation in some anovulatory premenopausal women (e.g., those with polycystic ovary syndrome), potentially increasing the risk of unintended pregnancy. Patients should be counseled accordingly.[48]

Clinically Significant Drug Interactions

While some general drug information resources may state that sitagliptin/metformin has no "severe" interactions, a detailed pharmacological review reveals numerous clinically significant interactions classified as "major" or "moderate" that necessitate careful management, dose adjustments, or avoidance.[20] These interactions can potentiate the risk of serious adverse effects or alter glycemic control.

Interactions Increasing Lactic Acidosis Risk

This is the most critical category of drug interactions. Any drug that can impair renal function, increase lactate production, or increase metformin accumulation can elevate the risk of MALA.

• Alcohol: This is a major interaction. Excessive alcohol consumption, whether acute ("binge" drinking) or chronic, potentiates the effect of metformin on lactate metabolism and can independently cause hypoglycemia or hyperglycemia. Patients must be strongly warned against excessive alcohol use.[1]
• Iodinated Contrast Media: Intravascular contrast agents can cause acute renal failure, leading to metformin accumulation. This interaction is a contraindication in patients with pre-existing renal dysfunction and requires temporary discontinuation of metformin in at-risk patients undergoing such procedures.[20]
• Carbonic Anhydrase Inhibitors: Drugs like topiramate and zonisamide can cause metabolic acidosis, which may be additive to the risk of MALA. More frequent monitoring is recommended.[1]
• Drugs Affecting Renal Function: Concomitant use of drugs that can negatively impact renal function, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and certain diuretics (e.g., furosemide), may increase the risk of metformin accumulation. Caution and regular monitoring of renal function are advised when these agents are used together.[86]

Interactions Increasing Hypoglycemia Risk

• Insulin and Insulin Secretagogues: The co-administration of sitagliptin/metformin with sulfonylureas (e.g., glimepiride, glipizide) or insulin significantly increases the incidence of hypoglycemia. To mitigate this risk, a reduction in the dose of the insulin or sulfonylurea is often required upon initiation of the combination therapy.[1]

Pharmacokinetic Interactions Affecting Metformin Levels

• Inhibitors of Renal Cationic Transporters: Metformin is eliminated via renal tubular secretion involving organic cation transporter-2 (OCT2) and multidrug and toxin extrusion (MATE) transporters. Drugs that inhibit these transporters can reduce metformin clearance and increase its systemic concentration, thereby increasing the risk of toxicity. Examples include ranolazine, vandetanib, dolutegravir, and cimetidine. The benefits and risks of co-administration should be carefully considered, and in some cases, dose limits on metformin may be recommended.[1]

Interactions Affecting Glycemic Control

• Drugs Causing Hyperglycemia: A number of medications can impair glucose tolerance and lead to a loss of glycemic control. These include thiazide diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, and sympathomimetics. When such drugs are administered to a patient on sitagliptin/metformin, the patient should be closely monitored for loss of blood glucose control. Conversely, when these drugs are withdrawn, the patient should be observed for hypoglycemia.[1]

The following table summarizes key drug interactions and provides clinical management recommendations.

Interacting Drug/Class	Mechanism of Interaction	Potential Clinical Effect	Clinical Management Recommendation
Alcohol	Potentiates metformin's effect on lactate metabolism; can cause hypoglycemia/hyperglycemia.	Increased risk of MALA; unpredictable effects on blood glucose.	Major Interaction. Advise patients to avoid excessive alcohol intake (acute or chronic).83
Iodinated Contrast Media	Can induce acute renal failure, leading to metformin accumulation.	Increased risk of MALA.	Contraindicated/Modify Therapy. Temporarily discontinue medication before and for 48 hours after the procedure in at-risk patients. Re-evaluate renal function before restarting.20
Carbonic Anhydrase Inhibitors (e.g., Topiramate)	Can cause metabolic acidosis.	Additive risk of MALA.	Moderate Interaction. Consider more frequent monitoring.1
NSAIDs (e.g., Ibuprofen)	May impair renal function.	Increased metformin levels and risk of MALA.	Moderate Interaction. Use with caution. Monitor renal function and for signs of lactic acidosis, particularly in patients with renal impairment.86
Insulin / Sulfonylureas	Pharmacodynamic synergism (increased insulin levels/action).	Increased risk of hypoglycemia.	Moderate Interaction. Monitor blood glucose closely. A dose reduction of the insulin or sulfonylurea may be required.1
OCT2/MATE Inhibitors (e.g., Ranolazine, Cimetidine)	Inhibit renal tubular secretion of metformin.	Increased metformin plasma concentrations and risk of toxicity.	Moderate/Major Interaction. Consider benefits vs. risks. May require metformin dose limitation or avoidance of combination.1
Corticosteroids, Thiazide Diuretics	Pharmacodynamic antagonism (hyperglycemic effects).	Loss of glycemic control.	Moderate Interaction. Monitor blood glucose closely for hyperglycemia. Observe for hypoglycemia if the interacting drug is discontinued.1

Regulatory and Historical Context

The global regulatory journey of the sitagliptin/metformin FDC reflects a consistent recognition of its clinical utility, coupled with an evolving understanding and management of its primary safety risks.

Approval in the United States (FDA)

In the United States, the Food and Drug Administration (FDA) has approved both immediate-release and extended-release formulations of the combination.

• Janumet (Immediate-Release): The initial FDC, Janumet, received its first FDA approval on March 30, 2007. This approval provided a new therapeutic option that combined the novel mechanism of a DPP-4 inhibitor with the established efficacy of metformin in a single tablet.[91]
• Janumet XR (Extended-Release): Recognizing the clinical importance of simplifying dosing regimens to improve patient adherence, an extended-release version, Janumet XR, was developed. It was approved by the FDA on February 2, 2012. This formulation offered the same powerful efficacy as the original but with the convenience of once-daily dosing.[4] The approval was based on clinical bioequivalence studies demonstrating that Janumet XR was equivalent to the co-administration of its individual components.[4]
• Generic Availability: Following the expiration of market exclusivity, generic versions of the sitagliptin/metformin combination have been approved, increasing accessibility.[91]

Approval in Australia (TGA)

In Australia, the Therapeutic Goods Administration (TGA) has approved sitagliptin/metformin FDCs, which are classified as Schedule 4 (Prescription Only Medicine).[91]

• Indications: The TGA-approved indications are broad, encompassing use as initial therapy for patients with high baseline HbA1c, as an adjunct to diet and exercise in patients inadequately controlled on monotherapy, and in combination with a sulfonylurea or insulin.[16]
• Regulatory Process: The extended-release formulation (Janumet XR) underwent a parallel TGA/Pharmaceutical Benefits Advisory Committee (PBAC) evaluation process to facilitate its listing on the Pharmaceutical Benefits Scheme (PBS), which subsidizes the cost of medicines for patients.[16] The TGA has also registered multiple generic versions of both the IR and XR formulations, such as those from Sandoz.[100]

Approval in the European Union (EMA)

In the European Union, the European Medicines Agency (EMA) has also granted marketing authorization for the sitagliptin/metformin combination (Janumet).

• Indications: The approved indications are similar to those in other regions, positioning the FDC as an adjunct to diet and exercise for patients inadequately controlled on metformin, or in various triple-therapy combinations.[91]
• Basis for Approval: The European Public Assessment Report (EPAR) for Janumet summarizes that the approval was based on a review of clinical studies demonstrating that the addition of sitagliptin to metformin provided clinically significant improvements in HbA1c levels compared to metformin alone. Bioequivalence studies confirmed that the FDC tablet delivered the active substances to the body in the same way as the individual tablets taken separately.[102]

A notable aspect of the drug's post-marketing history across all major regulatory domains has been the refinement of the contraindication related to renal impairment. Initial approvals were based on relatively conservative serum creatinine thresholds.[15] However, a growing body of evidence from medical literature and real-world use demonstrated that metformin could be used safely in patients with mild and some cases of moderate renal impairment.[76] This led regulatory agencies, including the FDA, to update the drug's labeling. The contraindication was changed from a fixed serum creatinine value to a more precise, risk-stratified approach based on the estimated glomerular filtration rate (eGFR).[66] This harmonization and evolution of safety guidelines represent a dynamic regulatory process that adapts to new scientific evidence, ultimately expanding safe access to an effective therapy for a larger patient population.

Conclusion

The fixed-dose combination of sitagliptin and metformin is a well-established, effective, and generally well-tolerated cornerstone in the management of type 2 diabetes mellitus. Its clinical utility is rooted in the complementary and additive pharmacological actions of its two components, which target multiple key pathophysiological defects of the disease: insulin resistance, impaired insulin secretion, and excessive hepatic glucose production.

Clinical evidence robustly demonstrates that the combination therapy provides superior glycemic control compared to monotherapy with either agent, leading to substantial reductions in HbA1c, fasting plasma glucose, and postprandial glucose. This enhanced efficacy is achieved with a low intrinsic risk of hypoglycemia and a favorable effect on body weight, which are significant clinical advantages over other classes of antihyperglycemic agents. The availability of both immediate-release and extended-release formulations offers flexibility, with the once-daily XR version providing a valuable option to simplify treatment regimens and potentially improve long-term patient adherence.

The safety profile is dominated by the well-known risks of metformin, most notably the rare but life-threatening risk of metformin-associated lactic acidosis. This necessitates rigorous patient selection, careful adherence to contraindications (especially regarding renal function), and ongoing monitoring. The sitagliptin component introduces a distinct set of potential, albeit less frequent, serious adverse events, such as pancreatitis, severe arthralgia, and rare hypersensitivity reactions, requiring continued clinical vigilance.

In conclusion, the sitagliptin/metformin FDC offers a powerful and convenient therapeutic option that aligns with modern strategies of early and effective combination therapy for T2DM. When prescribed with appropriate consideration for its contraindications, warnings, and the specific clinical profile of the patient, it plays a vital role in helping a broad range of individuals with type 2 diabetes achieve and maintain their glycemic targets.

Works cited

1. Metformin/Sitagliptin: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed October 2, 2025, https://www.rxlist.com/metformin_sitagliptin/generic-drug.htm
2. Sitagliptin and metformin (oral route) - Side effects & dosage - Mayo Clinic, accessed October 2, 2025, https://www.mayoclinic.org/drugs-supplements/sitagliptin-and-metformin-oral-route/description/drg-20559685
3. JANUMET® (sitagliptin and metformin HCl) & JANUMET® XR (sitagliptin and metformin HCl extended-release) | Official Site, accessed October 2, 2025, https://www.janumetxr.com/
4. FDA Approves JANUMET® XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of JANUMET® (sitagliptin/metformin HCl) Now Available with Once-Daily Convenience - Merck.com, accessed October 2, 2025, https://www.merck.com/news/fda-approves-janumet-xr-sitagliptin-and-metformin-hcl-extended-release-for-type-2-diabetes-offering-the-powerful-efficacy-of-janumet-sitagliptin-metformin-hcl-now-available-with-once/
5. Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellit - Dove Medical Press, accessed October 2, 2025, https://www.dovepress.com/sitagliptinmetformin-fixed-dose-combination-in-type-2-diabetes-mellitu-peer-reviewed-fulltext-article-DDDT
6. Original Article Efficacy and safety of sitagliptin in patients with type 2 diabetes mellitus: a meta-analysis, accessed October 2, 2025, https://e-century.us/files/ijcem/9/6/ijcem0021345.pdf
7. Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients - Diabetes & Metabolism Journal, accessed October 2, 2025, https://www.e-dmj.org/journal/view.php?doi=10.4093/dmj.2023.0128
8. Sitagliptin Metformin Combination Therapy - Consensus Academic Search Engine, accessed October 2, 2025, https://consensus.app/questions/sitagliptin-metformin-combination-therapy/
9. Sitagliptin And Metformin Combination Therapy - Consensus Academic Search Engine, accessed October 2, 2025, https://consensus.app/questions/sitagliptin-and-metformin-combination-therapy/
10. Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3047989/
11. Janumet: Uses, Side Effects, Dosage & More - GoodRx, accessed October 2, 2025, https://www.goodrx.com/janumet/what-is
12. Sitagliptin: MedlinePlus Drug Information, accessed October 2, 2025, https://medlineplus.gov/druginfo/meds/a606023.html
13. Janumet and Janumet XR: Side effects, dosage, price, and more - MedicalNewsToday, accessed October 2, 2025, https://www.medicalnewstoday.com/articles/drugs-janumet
14. What is JANUMET® XR (sitagliptin and metformin HCl extended-release)?, accessed October 2, 2025, https://www.janumetxr.com/what-is-janumet-xr/
15. Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3048013/
16. Metformin and Sitagliptin, tablet, 1000mg/50mg, 1000mg/100mg, Janumet® XR - November 2013 - PBS, accessed October 2, 2025, https://m.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2013-11/metformin-sitagliptin.html
17. Janumet Uses, Dosage & Side Effects - Drugs.com, accessed October 2, 2025, https://www.drugs.com/janumet.html
18. What is JANUMET® (sitagliptin and metformin HCl)?, accessed October 2, 2025, https://www.janumetxr.com/what-is-janumet/
19. JANUMET® (sitagliptin and metformin HCl) tablets - accessdata.fda.gov, accessed October 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022044s042lbl.pdf
20. Janumet, Janjumet XR (metformin-sitagliptin) dosing, indications ..., accessed October 2, 2025, https://reference.medscape.com/drug/janumet-janumet-xr-metformin-sitagliptin-342731
21. Clinical Use of DPP-4 Inhibitors - Frontiers, accessed October 2, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00389/full
22. DPP-IV Inhibitors | Johns Hopkins Diabetes Guide, accessed October 2, 2025, https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547042/all/DPP_IV_Inhibitors
23. The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect - MDPI, accessed October 2, 2025, https://www.mdpi.com/1660-4601/16/15/2720
24. Dipeptidyl Peptidase IV (DPP IV) Inhibitors - StatPearls - NCBI Bookshelf, accessed October 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK542331/
25. Dipeptidyl peptidase-4 inhibitor - Wikipedia, accessed October 2, 2025, https://en.wikipedia.org/wiki/Dipeptidyl_peptidase-4_inhibitor
26. Full article: Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes - Taylor & Francis Online, accessed October 2, 2025, https://www.tandfonline.com/doi/full/10.2147/dmsott.s4637
27. Glucophage® (Metformin Hydrochloride), the Wonder Drug: A Biguanide Class Treatment of Type 2 Diabetes - Methodist University, accessed October 2, 2025, https://www.methodist.edu/wp-content/uploads/2022/06/mr2017_wentling.pdf
28. Metformin - Wikipedia, accessed October 2, 2025, https://en.wikipedia.org/wiki/Metformin
29. Mechanism of Metformin: A Tale of Two Sites | Diabetes Care, accessed October 2, 2025, https://diabetesjournals.org/care/article/39/2/187/37215/Mechanism-of-Metformin-A-Tale-of-Two-Sites
30. Metformin: Uses, Interactions, Mechanism of Action - DrugBank, accessed October 2, 2025, https://go.drugbank.com/drugs/DB00331
31. Understanding the action mechanisms of metformin in the gastrointestinal tract - Frontiers, accessed October 2, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1347047/full
32. pmc.ncbi.nlm.nih.gov, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5552828/#:~:text=Metformin%20is%20a%20complex%20drug,1%20and%20alter%20the%20microbiome.
33. Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial - ResearchGate, accessed October 2, 2025, https://www.researchgate.net/publication/305892090_Effect_of_Sitagliptin_and_Metformin_on_Prediabetes_Progression_to_Type_2_Diabetes_-_A_Randomized_Double-Blind_Double-Arm_Multicenter_Clinical_Trial_Protocol_for_the_Sitagliptin_and_Metformin_in_PreDia
34. Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes - Dove Medical Press, accessed October 2, 2025, https://www.dovepress.com/article/download/5548
35. Effect of Initial Combination Therapy With Sitagliptin and Metformin - Page 4 - Medscape, accessed October 2, 2025, https://www.medscape.com/viewarticle/564095_4
36. Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes, accessed October 2, 2025, https://diabetesjournals.org/care/article/30/8/1979/28637/Effect-of-Initial-Combination-Therapy-With
37. Sitagliptin: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed October 2, 2025, https://www.medcentral.com/drugs/monograph/187692-307001/sitagliptin-oral
38. Sitagliptin Add-On Can Help Lower HbA1c Levels | MDedge - The Hospitalist, accessed October 2, 2025, https://blogs.the-hospitalist.org/content/sitagliptin-add-can-help-lower-hba1c-levels
39. In a New Study, Treatment With JANUMET® (sitagliptin/metformin), Merck's Diabetes Medicine, Resulted In Significantl | Fierce Biotech, accessed October 2, 2025, https://www.fiercebiotech.com/biotech/a-new-study-treatment-janumet%C2%AE-sitagliptin-metformin-merck-s-diabetes-medicine-resulted
40. Quantitative Models for Evaluating the Correlation between Baseline Hba1c Levels and Sitagliptin as Monotherapy or Dual Therapy Treatment in Type 2 Diabetes: A Meta-Regression Analysis, accessed October 2, 2025, https://clinmedjournals.org/articles/ijdcr/international-journal-of-diabetes-and-clinical-research-ijdcr-3-051.php?jid=ijdcr
41. Results of Phase III Studies of Sitagliptin, new oral treatment of diabetes,were presented by Merck & Co., Inc. at ADA, accessed October 2, 2025, https://www.ono-pharma.com/sites/default/files/en/news/press/enews20060612.pdf
42. Effects of sitagliptin combined with metformin for type 2 diabetes mellitus: a meta-analysis, accessed October 2, 2025, https://www.researchgate.net/publication/286635991_Effects_of_sitagliptin_combined_with_metformin_for_type_2_diabetes_mellitus_a_meta-analysis
43. Pharmacokinetic comparison of sitagliptin and metformin HCl extended-release tablets versus JANUMET® XR in healthy volunteers under fasting and fed conditions - Frontiers, accessed October 2, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1105767/full
44. Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study | PLOS One, accessed October 2, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0129477
45. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study - PubMed, accessed October 2, 2025, https://pubmed.ncbi.nlm.nih.gov/19232032/
46. Janumet Dosage Guide - Drugs.com, accessed October 2, 2025, https://www.drugs.com/dosage/janumet.html
47. Janumet Label - accessdata.fda.gov, accessed October 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022044s035lbl.pdf
48. Label: JANUMET XR- sitagliptin and metformin hydrochloride tablet, film coated, extended release - DailyMed, accessed October 2, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64beb3d2-3aeb-4cd5-ba11-dacf6c9a5b50
49. Janumet XR (sitagliptin and metformin) tablets ... - accessdata.fda.gov, accessed October 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202270s003lbl.pdf
50. Metformin / Sitagliptin Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed October 2, 2025, https://www.drugs.com/dosage/metformin-sitagliptin.html
51. Janumet XR Dosage Guide - Drugs.com, accessed October 2, 2025, https://www.drugs.com/dosage/janumet-xr.html
52. How to Take JANUMET® (sitagliptin and metformin HCl), accessed October 2, 2025, https://www.janumetxr.com/how-to-take-janumet/
53. How to Take JANUMET® XR (sitagliptin and metformin HCl extended-release), accessed October 2, 2025, https://www.janumetxr.com/how-to-take-janumet-xr/
54. janumet_xr_pi.pdf - Merck.com, accessed October 2, 2025, https://www.merck.com/product/usa/pi_circulars/j/janumet_xr/janumet_xr_pi.pdf
55. Janumet Side Effects: What to Expect When Taking It - GoodRx, accessed October 2, 2025, https://www.goodrx.com/janumet/common-side-effects
56. www.webmd.com, accessed October 2, 2025, https://www.webmd.com/drugs/2/drug-148063-938/sitagliptin-metformin-oral/sitagliptin-metformin-oral/details#:~:text=Nausea%2C%20vomiting%2C%20stomach%20upset%2C,tell%20your%20doctor%20right%20away.
57. Janumet and Janumet XR: Side Effects and Their Treatments - Healthline, accessed October 2, 2025, https://www.healthline.com/health/drugs/janumet-side-effects
58. Metformin and sitagliptin Uses, Side Effects & Warnings - Drugs.com, accessed October 2, 2025, https://www.drugs.com/mtm/metformin-and-sitagliptin.html
59. janumet - Merck.com, accessed October 2, 2025, https://www.merck.com/product/usa/pi_circulars/j/janumet/janumet_mg.pdf
60. Janumet side effects and how to avoid them - SingleCare, accessed October 2, 2025, https://www.singlecare.com/blog/janumet-side-effects/
61. Label: JANUMET- sitagliptin and metformin hydrochloride tablet, film coated - DailyMed, accessed October 2, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b55ee3d9-7f0b-4dd9-9213-fbc69f09f567&audience=consumer
62. Possible Side Effects of JANUMET® (sitagliptin and metformin HCl), accessed October 2, 2025, https://www.janumetxr.com/janumet-side-effects/
63. Metformin and Fatal Lactic Acidosis - Medsafe, accessed October 2, 2025, https://www.medsafe.govt.nz/profs/puarticles/5.htm
64. FDA SAFETY ANNOUNCEMENTS FOR METFORMIN - NCBI, accessed October 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK409379/
65. Metformin-Associated Lactic Acidosis (MALA) - StatPearls - NCBI Bookshelf, accessed October 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK580485/
66. Metformin/sitagliptin Disease Interactions - Drugs.com, accessed October 2, 2025, https://www.drugs.com/disease-interactions/metformin-sitagliptin.html
67. Frequently Asked Questions About JANUMET® (sitagliptin and metformin HCl), accessed October 2, 2025, https://www.janumetxr.com/janumet-faqs/
68. Janumet (sitagliptin/metformin) - Healthgrades Health Library, accessed October 2, 2025, https://resources.healthgrades.com/drugs/janumet
69. What lactic acidosis symptoms are caused by metformin? - Drugs.com, accessed October 2, 2025, https://www.drugs.com/medical-answers/what-symptoms-lactic-acidosis-caused-metformin-3573882/
70. Metformin associated lactic acidosis - The BMJ, accessed October 2, 2025, https://www.bmj.com/content/339/bmj.b3660
71. Individualize the dosage of JANUMET on the basis of the patient's o o The most common adverse reactions report - Merck.com, accessed October 2, 2025, https://www.merck.com/product/usa/pi_circulars/j/janumet/janumet_pi.pdf
72. Sitagliptin Phosphate-Metformin Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed October 2, 2025, https://www.webmd.com/drugs/2/drug-148063-938/sitagliptin-metformin-oral/sitagliptin-metformin-oral/details
73. Possible Side Effects of JANUMET® XR (sitagliptin and metformin HCl extended-release), accessed October 2, 2025, https://www.janumetxr.com/janumet-xr-side-effects/
74. pdf.hres.ca, accessed October 2, 2025, https://pdf.hres.ca/dpd_pm/00077248.PDF
75. Sitagliptin/Metformin hydrochloride SUN 50 mg/850 mg film-coated, accessed October 2, 2025, https://www.ema.europa.eu/en/documents/product-information/sitagliptin-metformin-hydrochloride-sun-epar-product-information_en.pdf
76. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency | Diabetes Care, accessed October 2, 2025, https://diabetesjournals.org/care/article/34/6/1431/27322/Use-of-Metformin-in-the-Setting-of-Mild-to
77. FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function, accessed October 2, 2025, https://www.fda.gov/files/drugs/published/Drug-Safety-Communication-FDA-revises-warnings-regarding-use-of-the-diabetes-medicine-metformin-in-certain-patients-with-reduced-kidney-function-%28PDF%29.pdf
78. Janumet (Sitagliptin / Metformin) Dosage Guide - GoodRx, accessed October 2, 2025, https://www.goodrx.com/janumet/janumet-dosage
79. Metformin (oral route) - Side effects & dosage - Mayo Clinic, accessed October 2, 2025, https://www.mayoclinic.org/drugs-supplements/metformin-oral-route/description/drg-20067074
80. Metformin/sitagliptin Interactions - Drugs.com, accessed October 2, 2025, https://www.drugs.com/drug-interactions/metformin-sitagliptin.html
81. www.rxlist.com, accessed October 2, 2025, https://www.rxlist.com/metformin_sitagliptin/generic-drug.htm#:~:text=What%20Other%20Drugs%20Interact%20with%20Metformin%2FSitagliptin%3F,-If%20your%20medical&text=Metformin%2FSitagliptin%20has%20severe%20interactions%20with%20no%20other%20drugs.
82. www.wellrx.com, accessed October 2, 2025, https://www.wellrx.com/janumet/lifestyle-interactions/#:~:text=JANUMET%20Lifestyle%20Interactions&text=Notes%20for%20Consumers%3A%20Do%20not,dangerously%20high%20lactic%20acid%20levels.
83. Janumet and Alcohol/Food Interactions - Drugs.com, accessed October 2, 2025, https://www.drugs.com/food-interactions/metformin-sitagliptin,janumet.html
84. Alcohol and metformin: Interactions, side effects, and complications - MedicalNewsToday, accessed October 2, 2025, https://www.medicalnewstoday.com/articles/317311
85. Label: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE tablet, film coated - DailyMed, accessed October 2, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d812277-21a8-4de3-b728-e3fdd01305b5
86. www.drugs.com, accessed October 2, 2025, https://www.drugs.com/drug-interactions/ibuprofen-with-metformin-sitagliptin-1310-0-1576-0.html?professional=1#:~:text=MANAGEMENT%3A%20Caution%20and%20monitoring%20of,in%20patients%20with%20renal%20impairment.
87. Ibuprofen and metformin / sitagliptin Interactions - Drugs.com, accessed October 2, 2025, https://www.drugs.com/drug-interactions/ibuprofen-with-metformin-sitagliptin-1310-0-1576-0.html
88. Ibuprofen and metformin / sitagliptin Interactions - Drugs.com, accessed October 2, 2025, https://www.drugs.com/drug-interactions/ibuprofen-with-metformin-sitagliptin-1310-0-1576-0.html?professional=1
89. Taking metformin with other medicines and herbal supplements - NHS, accessed October 2, 2025, https://www.nhs.uk/medicines/metformin/taking-metformin-with-other-medicines-and-herbal-supplements/
90. Janumet Food, Alcohol, Supplements and Drug Interactions - ScriptSave WellRx, accessed October 2, 2025, https://www.wellrx.com/janumet/lifestyle-interactions/
91. Sitagliptin/metformin - Wikipedia, accessed October 2, 2025, https://en.wikipedia.org/wiki/Sitagliptin/metformin
92. Janumet (metformin and sitagliptin) FDA Approval History - Drugs.com, accessed October 2, 2025, https://www.drugs.com/history/janumet.html
93. Drug Approval Package: Janumet (Sitagliptin/Metformin Hydrochloride) NDA #022044, accessed October 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022044TOC.cfm
94. www.fda.gov, accessed October 2, 2025, https://www.fda.gov/media/181808/download#:~:text=Janumet%20was%20first%20approved%20by,2%20diabetes%20mellitus%20(T2DM).
95. FDA approves extended-release tablets for type 2 diabetes - Drug Topics, accessed October 2, 2025, https://www.drugtopics.com/view/fda-approves-extended-release-tablets-type-2-diabetes
96. Lupin Receives Tentative Approval from U.S. FDA for Sitagliptin and Metformin Hydrochloride Tablets, accessed October 2, 2025, https://www.lupin.com/lupin-receives-tentative-approval-from-u-s-fda-for-sitagliptin-and-metformin-hydrochloride-tablets/
97. Sitagliptin (Apo) | healthdirect, accessed October 2, 2025, https://www.healthdirect.gov.au/medicines/brand/amt,992051000168103/sitagliptin-apo
98. JANUMET® (sitagliptin phosphate monohydrate/metformin hydrochloride) 50 mg/500 mg, 50 mg/85 - Medsinfo, accessed October 2, 2025, https://rss.medsinfo.com.au/mk/pi.cfm?product=mkpjanum
99. Australian Public Assessment Report for Sitagliptin/Metformin - Therapeutic Goods Administration (TGA), accessed October 2, 2025, https://www.tga.gov.au/sites/default/files/auspar-sitagliptin-130114.pdf
100. SITAGLIPTIN/METFORMIN SANDOZ XR 100/1000 sitagliptin (as hydrochloride monohydrate)/metformin HCl 100mg/1000mg extended release tablet bottle (369590) | Therapeutic Goods Administration (TGA), accessed October 2, 2025, https://www.tga.gov.au/resources/artg/369590
101. Sitagliptin/Metformin Sandoz 50/1000 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 50 mg/1000 mg film coated tablet blister pack (326500) | Therapeutic Goods Administration (TGA), accessed October 2, 2025, https://www.tga.gov.au/resources/artg/326500
102. Janumet | European Medicines Agency (EMA), accessed October 2, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/janumet
103. JANUMET label - accessdata.fda.gov, accessed October 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022044s022lbl.pdf